Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cycloserine→

Cycloserine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
68-41-7
Molecular formula
C3H6N2O2
Molecular weight
102.0919 g/mol
Drug class
Second-line antitubercular antibioticD-alanine analogue
Mechanism of action
Inhibits alanine racemase and D-alanine:D-alanine ligase, enzymes required for bacterial peptidoglycan synthesis, impairing mycobacterial cell-wall formation.
Indications / reported uses
  • Treatment of active tuberculosis caused by susceptible Mycobacterium tuberculosis as part of a multidrug regimen when first-line or preferred agents cannot be used or drug resistance is present; specialist monitoring is required due to neuropsychiatric toxicity

Sources: WHO consolidated guidelines on tuberculosis, Module 4: drug-resistant TB · US DailyMed — Cycloserine capsules · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cycloserine Environmental Risk Assessment (ERA) (the Cycloserine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.